Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
RenovoRx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RNXT
Nasdaq
8731
https://renovorx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for RenovoRx Inc
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
- Apr 18th, 2024 12:30 pm
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
- Apr 16th, 2024 12:30 pm
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
- Apr 15th, 2024 12:00 pm
RenovoRx Announces $11.1 Million at Market Private Placement
- Apr 8th, 2024 12:30 pm
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
- Apr 5th, 2024 12:30 pm
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
- Mar 12th, 2024 1:00 pm
RenovoRx Highlights Key Leadership Promotions
- Mar 8th, 2024 9:05 pm
RenovoRx CEO Issues Letter to Shareholders
- Feb 6th, 2024 1:30 pm
RenovoRx Closes $6.1 Million Private Placement
- Jan 29th, 2024 1:30 pm
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
- Dec 21st, 2023 1:30 pm
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
- Dec 19th, 2023 1:30 pm
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
- Dec 13th, 2023 1:31 pm
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
- Nov 16th, 2023 1:35 pm
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
- Nov 14th, 2023 1:30 pm
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
- Oct 2nd, 2023 12:30 pm
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
- Aug 17th, 2023 12:30 pm
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
- Jul 31st, 2023 12:30 pm
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
- Jul 20th, 2023 12:00 pm
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
- Jun 29th, 2023 12:00 pm
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
- Jun 20th, 2023 12:30 pm
Scroll